Efficacy and safety of the switch from etanercept biosimilar to another biosimilar in patients with rheumatoid arthritis
2020 Volume 32 Issue 3 Pages 245-250
Details
2020 Volume 32 Issue 3 Pages 245-250
Recently, biosimilars（BS）have been used for the treatment of rheumatoid arthritis. Many clinical studies have demonstrated that switching from reference product biologics to BSs present no problems with efficacy or safety. However, no clinical study has switched from one BS to another. Therefore, 102 patients who had been treated with etanercept BS（ETN-BS, LBEC0101）for more than 12 weeks and had a remission of DAS28-CRP were analyzed after switching to another ETN-BS（YLB113）for 12 weeks or longer. Remission was maintained after the ETN-BS was changed to another ETN-BS. However, 9 cases returned to the previous BS. The reasons were subcutaneous injection pain in 6 cases, itchy skin in 2 cases, and redness at the injection site in 1 case. There was no difference in efficacy between the BSs but adverse events were different. Therefore, switching between BSs is possible but should be done carefully.
